Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 583

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 583
---
62.65 |
| Pfizer Inc.                         |     | -NYSE:PFE      |     | Pharmaceutical |     |         0.54 |     |           0.40 |     | 160.37 |     | 69.86 |
| Bristol-Myers Squibb Company        |     | -NYSE:BMY      |     | Pharmaceutical |     |         0.51 |     |           0.36 |     | 100.07 |     | 52.39 |
| Gilead Sciences, Inc.               |     | -NasdaqGS:GILD |     | Pharmaceutical |     |         0.31 |     |           0.26 |     |  91.86 |     | 23.35 |
| Biogen Inc.                         |     | -NasdaqGS:BIIB |     | Pharmaceutical |     |         0.68 |     |           0.58 |     |  29.41 |     |  6.93 |
| Amarin Corporation plc              |     | -NasdaqGM:AMRN |     | Pharmaceutical |     |         1.53 |     |           1.53 |     |   0.25 |     |  0.00 |
| Average – Biotechnology             |     |                |     |                |     |         0.69 |     |           0.66 |     |   27.3 |     |   0.8 |
| Average – Pharmaceutical            |     |                |     |                |     |         0.61 |     |           0.54 |     |  244.5 |     |  39.4 |
| Average – General                   |     |                |     |                |     |         0.66 |     |           0.61 |     |  110.9 |     |  15.7 |

| Moore Financial Consulting |

Annex E-31

Dear Sir, Upon your request, Moore Financial Consulting Ltd. (hereinafter: “MFC”), performed a valuation of NLS Pharmaceutics AG. (“NLS”, “the Company”) as of December 19, 2024. Our study was performed based on the following: •NLS’s annual financial report as of 31.12.2023 •NLS proforma financial report as of 30.06.2024 •N